Application of bog bilberry shoots as medication, demonstrating activation of glucose absorption by ischemic brain in treatment of type ii diabetes mellitus

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmacology and is intended for extension of nomenclature of herbal medications for treatment of diabetes mellitus. Medication, representing bog bilberry shoots, demonstrates activation of glucose absorption by ischemic brain in treatment of type II diabetes mellitus. Studies were Indices of glucose-tolerant test at initial level, 30, 60, 120 minutes after glucose loading, as well as level of glucosuric activity. At the background of experimental DM utilisation of glucose by ischemic brain was determined by arterial-venous difference.

EFFECT: obtained results substantiate possibility of bog bilberry shoots application in clinic.

1 tbl

 

The invention relates to medicine, in particular to pharmacology, and is intended to expand the Arsenal of herbal medicines for the treatment of diabetes, including affecting the correction of metabolic disorders of the brain in diabetes.

It is known that drugs from plants can be used for the prevention and treatment of insulin-independent diabetes (type II DM). Polivalentes the chemical composition of the herbal remedies are able to provide compensation for metabolic disorders and affect pathogenetic links of type II DM. A wide range of pharmacological activity and low toxicity of medicinal plants makes their use as a means of additional therapy [Pastushenkov", L.V. Pharmacotherapy with the basics of phytotherapy / Lavastuseks, ESA - SPb.: SPVI, 1995. - 250 S.; Pastushenkov", L.V. Medicinal plants: use in folk medicine and in everyday life / Lavastuseks, Alastorko, Vlastislav. - Leningrad: Lenizdat. - 1990. - 384 S.].

To official hypoglycemic remedies of plant origin include bilberry shoots, which are used as an independent tool in additional therapy diabetes type II and is part of the collection "Arfazetin" [the State Register of medicines. - M.: 2002. - 1300 C.].

On territory and Russia grows several species of Blueberries, including blueberry. Distribution and stocks of raw materials blueberry is not inferior to the ordinary blueberry. However, in the official medicine blueberry shoots are not used due to sufficiently studied this plant. In the literature there is a link on the hypoglycemic activity of blueberry [Keith, S.M. ABOUT sugar-lowering action of some medicinal plants / Smith, Gil // Medical business. - 1960. No. 6. - S-622; Herbal preparations in the treatment of patients with diabetes mellitus / Smith, Istencin, Uscit etc. // Medical business. - 1987. No. 7. - S-711; Choi Thesep. Medicinal plants / Choi Thesop; translated from the Korean Vindictively and others - M., 1987. - 608 S.], however, the publications devoted to the study of the hypoglycemic effect of blueberry shoots, no.

As a prototype of the selected bilberry [Plant resources of the USSR. Flowering plants, their chemical composition, use: Family Paeoniaceae - Thymeleaceae. - L.: Nauka, 1985. - 357 S.], similar to the blueberry in Botanical terms, and similar in chemical composition.

Object of the invention is the rationale for the use of blueberry shoots as antidiabetics.

The technical result is to evaluate the hypoglycemic effect of blueberry shoots and effect on glucose utilization by the brain against SD.

The technical result is achieved in experiments the E. 32 rats male Wistar weighing 200-220 g The effect is set on two models. The first model, a single glucose load, in which experimental animals, pre-starving within 24 hours, oral tube was injected with freshly prepared in accordance with the requirements of the global Fund XI infusions (1:10), and the animals of group I - infusion shoots blueberry, group II - infusion shoots bilberry III (control) group saline at an equivalent volume. The research was administered in the dose of 10 ml/kg over 40 minutes before the injection of glucose.

Next to rats orally injected with a glucose solution at the rate of 2 g/kg (20% aqueous solution in a dose of 10 ml/kg). Blood sampling was obtained from the tail vein of the animal under light ftorotanovom anesthesia before the introduction and after 30, 60 and 120 minutes after administration of glucose (GTT). The concentration of glucose in blood was assessed by using a set of "PHOTOPULSE" LLC "Impact". According to the obtained points were built ("sugar") curves [Guskov T.A. Rules of pre-clinical studies the safety and efficacy of pharmacological substances. Rules quality laboratory practice in RF - G L P or RDI. - M, JSC JJA "Remedium", 2000. - P.7-24].

Glycosylase effect was determined by the level of glucose in the urine within 3 hours after a carbohydrate load.

The second animal model caused the former is elementally diabetes by fractional subcutaneous injection of alloxan (twice with an interval in a dose of 90 mg/kg) animals, pre starving 24 hours. During the whole experimental period (21 days) the animals of the experimental groups received freshly prepared in accordance with the requirements of GFH extracts of bilberry and blueberry, in the dose of 10 ml/kg (daily dose) oral tube. The control group was injected with saline in equivalent amounts.

On day 21 of the experiment was simulated cerebral ischemia by occlusion of the carotid arteries and decrease systemic arterial pressure to 40 mm Hg for 8 minutes Then collected the venous blood from the effluent venous sinuses, blood from the carotid arteries. In blood after acute cerebral ischemia was determined by glucose, as described above. On arterio-venous difference in expected utilization of glucose by the brain [Pogorelov, V.E. Mechanism cerebroprotective steps of Cavinton in conditions of brain ischemia / Weepily, Medgyesy, Achiridae and other Pyatigorsk, 1998. - 27. - Dept. in VINITI 12.11.98, No. 3268 - 98].

Statistical analysis was performed within a series of t-criterion of student, between the series - on the criterion of inversions of Wilkonson-Mann-Whitney.

When conducting glucose tolerance test (model 1) set the hypoglycemic activity of blueberry shoots. It is revealed that the concentration of glucose in blood of the control group vividly the data to the end of the experiment was 57.6% above baseline, in the group of animals treated with extract of bilberry shoots, the glucose content was 12.2% higher than the original, in the group treated with the preparation of the blueberry, the same figure was 3.1% below baseline (table 1).

Table 1
Hypoglycemic activity of extracts of blueberry and bilberry when performing a glucose tolerance test
Groups of animalsThe content of glucose in the blood
sourceafter 30 minutesafter 60 minutesafter 120 minutes
abs. Val. mmol/labs. Val. mmol/l%abs. Val. mmol/l%abs. Val. mmol/l%
Blueberry6,5±0,46,8±0,3*+4,66,2±0,3*-4,66,3±0,3 *-3,1
Bilberry5,8±0,66,5±0,5*+12,26,9±0,5*+18,96,5±0,5*+12,2
Control6,6±0,48,4±0,8#+27,210,1±0,5#+53,010,4±0,5#+57,6
Note: % - shows the changes relative to the original data,
* indicated statistically significant changes compared to control animals (P<0,05),
# indicated a statistically significant change compared with the initial data (P<0,05).

Determination of glycosidically activity showed that an increase in the excretion of glucose in urine in the 2nd hour of the experiment relative to the control group amounted to groups that received infusion of bilberry, 99%for the group treated with infusion of blueberries, 122%.

Analysis of the results of studies on glucose utilization chemisorbant brain showed that exchange application of extracts of bilberry is not conducive to the preservation of glucose utilization by the brain (-20%), and the application of the blueberry and tiviral 170%.

The results obtained in the study of the extracts of shoots promising plants blueberry indicate

benefits of blueberry compared with blueberries ordinary in connection with marked activation of absorption of glucose chemisorbant brain on the background of experimental diabetes,

significant hypoglycemic and glucosuria the effect of this plant.

The use of blueberry shoots as a means of exhibiting enhanced absorption of glucose chemisorbant the brain in the treatment of diabetes mellitus type II.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmacology and is intended for extension of nomenclature of herbal medications for treatment of diabetes mellitus (DM). Studied are properties of Vaccinium axillare Nakai shoots, Far East plant, which had not been studied before. Glucose-tolerant test, made on male rats of Wistar line with weight 200-220 g, showed reliable hypoglycemic and glucosuric action of Vaccinium axillare Nakai shoots. Hypoglycemic effect of Vaccinium axillare Nakai is also confirmed in experiment on alloxan diabetes model. It has been established that newly studied plant activates glucose utilisation by brain, aggravated by angiopathy, at the background of alloxan diabetes.

EFFECT: obtained results indicate that Vaccinium axillare Nakai shoots have hypoglycemic and glucosuric effect and that new object has advantage in comparison with Vaccinium myrtillus due to more expressed hypoglycemic action and ability to activate glucose utilisation by brain in case of DM.

1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I): where: A is a monocyclic or polycyclic aryl or heteroaryl group, where the heteroaryl radical denotes a 5-10-member cyclic system containing at least one heteroaromatic ring and containing at least one heteroatom selected from O, S and N; optionally substituted with one or more substitutes independently selected from a group comprising halogen atoms, C1-4alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C1-4alkoxy and a hydroxyl group; B is a monocyclic nitrogen-containing heteroaryl group, where the heteroaryl radical denotes a 5-6-member heteroaromatic ring containing at least one heteroatom selected from S and N; optionally substituted with one or more substitutes selected from a group consisting of halogen atoms, C1-4alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, aryl and C1-8alkylthio; either a) R1 is a group of formula: -L-(CR'R")n-G, where L is a binding group selected from a group consisting of a direct bond, -(CO)-, -(CO)NR'- and -SO2-; R' and R" is independently selected from hydrogen atoms; n assumes values from 0 to 1; and G is selected from a group consisting of a hydrogen atom and C1-4alkyl, aryl, heteroaryl, where the heteroaryl radical denotes a 5-6-member heteroaromatic ring containing at least one heteroatom selected from O, S and N; C3-8cycloalkyl and saturated heterocyclic groups, where heterocyclic group denotes a non-aromatic saturated 6-member carbocyclic ring in which one or two carbon atoms are substituted with a N heteroatom; where alkyl, C3-8cycloalkyl, aryl or heteroaryl groups are unsubstituted or substituted with one or more substitutes selected from halogen atoms; and R2 is a group selected from hydrogen atoms, halogen atoms and C1-4alkyl, C2-5alkynyl, C1-4alkoxy, -NH2 and cyano groups, where alkyl and alkynyl groups may be unsubstituted or substituted with one aryl group; or b) R2, R1 and -NH- group to which R1 is bonded form a group selected from groups of formulae and , where: Ra is selected from a hydrogen atom or groups selected from C1-4alkyl, C3-8cycloalkyl, aryl, aryl-C1-4alkyl, heteroaryl, where the heteroaryl radical denotes a 5-6-member heteroaromatic ring containing at least one heteroatom selected from O and N; saturated heterocyclic rings, where the heterocyclic group denotes a non-aromatic saturated 6-member carbocyclic ring in which one carbon atom is substituted with a heteroatom selected from O and N; and C1-4alkylthio; where the aryl or heteroaryl groups are unsubstituted or substituted with one or more groups selected from halogen atoms, cyano group, trifluoromethoxy and carbamoyl; Rb denotes hydrogen; and pharmaceutically acceptable salts thereof and N-oxides; provided that the compound is not selected from N-[6-(1-methyl-1H-indol-3-yl)-5-pyridin-2-ylpyrazin-2-yl]benzamide, N-[3-ethoxycarbonyl-6-(1-methyl-1H-indol-3-yl)-5-pyridin-2-ylpyrazin-2-yl]benzamide, and N-[3-ethoxycarbonyl-6-(1-methyl-1H-indol-3-yl)-5-pyridin-2-ylpyrazin-2-yl]formamide. The invention also relates to a pharmaceutical composition, use of compounds in any of claims 1-20, a method of treating a subject, as well as a composite product.

EFFECT: obtaining novel biologically active compounds having adenosine A2B receptor antagonist activity.

27 cl, 160 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: described are compounds of formula I , where R1 and R2, together with carbon atoms Ca and Cb to which they are bonded, form or R3, R5, R6 and R7 independently denote hydrogen, C1-C6alkyl or C3-C8cycloalkyl; and R4 denotes 2,2-dimethylpropyl, 3-methylbutyl, isopropyl, tert-butyl, cyclopropylmethyl, cyclopentylmethyl, 3,3-dimethylbutyl or 1-cyclopropyl-1-methylethyl. The invention also relates to pharmaceutically acceptable salts of such compounds and pharmaceutical compositions containing such compounds of salts thereof. The disclosed compounds and compositions are capable of inhibiting activity of the 11-β-hydroxysteroid dehydrogenase 1 (11-β-HSD1) enzyme.

EFFECT: possibility of using derivatives for treating and preventing diabetes, obesity, eating disorders, dyslipidaemia and hypertension.

22 cl, 1 tbl, 27 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts thereof where R1 and R2 together denote a group selected form groups of formula (III-1): , where R9 denotes 1) a lower alkyl group, optionally substituted with a halogen atom or lower alkoxy group, 2) an aryl group, 3) an aralkyl group, 4) a heteroarylalkyl group, 5) a heteroaryl group, where the aryl, aralkyl, heteroarylalkyl and heteroaryl groups can be substituted with a halogen atom, lower alkyl group, optionally substituted with a lower alkoxy group or 1-3 halogen atoms, lower alkoxy group, optionally substituted with 1-3 halogen atoms, cyano group, hydroxy group, alkylsulphonyl group, cycloalkylsulphonyl group, aryl group, heteroaryl group, alkylaminocarbonyl group, alkanoyl amino group, alkyl amino group or dialkylamino group; R10 denotes a lower alkyl group, optionally substituted with 1-3 halogen atoms, or a lower alkylsulphonyl group; X9-X12 denotes a carbon atom or a nitrogen atom, where the carbon atom can be independently substituted with a lower alkyl group, optionally substituted with a halogen atom or a lower alkoxy group, lower alkoxy group, optionally substituted with a halogen atom, or a cyano group or a halogen atom; R3 denotes a) a group of formula (II-1): (ii-U where R4 and R5, taken together with a nitrogen atom, form a 5- or 6-member monocyclic ring, where the monocyclic ring may contain a substitute in form of a lower alkyl group, m1 equals 3; or b) a group of formula (II-2): , where R6 denotes a lower alkyl group or cycloalkyl group; m2 equals 1 or 2; X1-X4 all denote carbon atoms, or one of X1-X4 denotes a nitrogen atom and the rest denote carbon atoms; and where "heteroaryl" in each case relates to a 5- or 6-member aromatic ring containing 1-3 heteroatoms selected from a nitrogen atom, oxygen atom and a sulphur atom. The invention also relates to a histamine H3 receptor antagonist or inverse agonist, as well as a preventive or medicinal agent.

EFFECT: obtaining novel biologically active compounds, having histamine H3 receptor antagonist or inverse agonist activity.

11 cl, 8 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) where R1 is chosen from a group consisting of phenyl, unsubstituted or substituted by one or two groups independently chosen from (lower) alkyl, (lower) phenylalkyl wherein a phenyl ring can be unsubstituted or substituted by one or two groups independently chosen from halogen; R2 represents hydrogen; or R1 and R2 together with nitrogen atom whereto attached, form a saturated 5- or 6-members heterocyclic ring optionally containing an additional oxygen heteroatom, said saturated heterocyclic ring is unsubstituted or substituted by one, two or three groups independently chosen from (lower) alkyl, halogen; R3 is chosen from a group consisting of hydrogen, (lower) alkyl, (lower) hydroxyalkyl, (lower) alkoxyalkyl, (lower) haloalkyl, (lower) cycloalkylalkyl, (lower) cyanoalkyl, (lower) alkylsulfonyl, phenyl unsubstituted or substituted by one or two groups independently chosen from halogen; R4 represents hydrogen or halogen; R5 represents a group chosen from where m represents 0 or 1; n represents 0,1 or 2; X represents CR13R13'; R6, R6', R7, R7', R8,R8', R13, R13' are independently chosen from a group consisting of hydrogen, (lower) alkyl, halogen; p represents 0 or 1; R9 is chosen from (lower) alkyl, cycloalkyl, (lower) cycloalkylalkyl; q represents 0 or 1; R10 represents (lower) alkyl; and to their pharmaceutically acceptable salts, as well as to a pharmaceutical composition exhibiting histamine 3 receptor antagonistic and/or antagonistic activity and based on the compounds of formula I.

EFFECT: there are prepared and described new compounds which can be effective in treatment and/or prevention of the diseases associated with H3 receptor modulation.

24 cl, 34 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns Seakem Gold agarose coated granules containing secretory cells.

EFFECT: invention provides the smallest tissues inflammation in recipients.

40 cl, 8 ex, 1 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to drugs, and concerns an application of an LXR agonist for preparing a drug effective for treatment and/or prevention of type I diabetes and a method of increasing primary pancreatic islet viability ex vivo wherein said pancreatic islets contact with the LXR agonist.

EFFECT: extended range of products for type I diabetes treatment.

13 cl, 8 dwg, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a group of compounds of general formula (I) (where substitute Q-A is on a ring atom, which is separated by two atoms from the ring atom directly bonded to the substituted glucitol group), where R1, R2, R3 and R4 are each independently selected from hydrogen, -C(=O)Rx and alkyl, which can be substituted with one or more Ra, where Ra is phenyl and Rx is alkyl; Ar1 is a benzene ring which can be substituted with alkyl or halogen, a thiophene ring or pyrazine ring; Q is -(CH2)m-(L)p-; m is an integer from 0 to 2, n is equal to 1 or 2, p is equal to 0 or 1; L is -O-, A is a phenyl which can be substituted with one or more Rb, naphthyl or a 5-10-member aromatic heterocyclic group containing a nitrogen or sulphur atom; Rb is independently selected from alkenyl, alkynyl, halogen, hydroxyl, cyano group, carboxyl group, alkoxy group, which can be substituted with one or more Rc, phenyl, alkylthio group, alkylsulphonyl group, -NRfRg, alkylcarbonyl group, alkoxycarbonyl group, alkylenedioxy group, pyrazolyl group and tetrahydrofuranyloxy group; Re is independently selected from halogen, hydroxyl and phenyl; Rf is hydrogen and Rg is alkylcarbonyl, or pharmaceutically acceptable salts thereof. The invention also relates to a group of specific compounds having general formula (I). The invention also pertains to a group of intermediate compounds of compounds of general formula (Ib), which are used in synthesis of compounds of formula (Ia) (special case of formula I). The invention also relates to pharmaceutical compositions based on compounds of formula (I) for use as an inhibitor or Na+-glucose II cotransporter, as well as for use in preventing or treating diabetes, hyperglycemia, caused by hyperglycemia of diabetic complications, or obesity. The invention also relates to a method of preventing or treating diabetes caused by hyperglycemia of diabetic complications or obesity by administering a therapeutically effective amount of the compound of formula (I) to a patient.

EFFECT: high effectiveness of the compounds.

15 cl, 10 tbl, 48 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a chrysophanol conjugate or its derivative, characterised by general formula (I), in which R1-R8 is a group selected from -H, -OH, -OCH3, -CH3, provided that not less than two groups from R1-R8 denote -H or provided that one or two of groups R2, R3, R6 and R7 are a -COOH group, M is a nitrogen organic base selected from a group comprising chitosamin, glucosamin, or a basic amino acid selected from a group comprising arginine, lysine, carnitine, and group M is bonded to the chrysophanol part in the conjugate.

EFFECT: invention relates to use of the conjugate as a medicinal agent for preventing or treating diabetic nephropathy, osteoarthritis, rheumatic or rheumatoid arthritis, intestinal adhesion, intestinal peristalsis restoration, and a medicinal agent based on the conjugate.

8 cl, 4 dwg, 57 ex, 18 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: offered is the application of hyaluronidase immobilised by electron-beam synthesis nanotechnology as a hypoglycemic agent effective in non-insulin-dependent diabetes mellitus. The mechanism of action is supposed to be modification of the properties of hyaluronic acid of cell glycocalyx and receptors to insulin It is accompanied by higher ligand sensitivity.

EFFECT: in non-insulin-dependent hyperglycemia, immobilised hyaluronidase caused peripheral blood sugar level decreasing by 41,9 %; insulin concentration has been decreasing statistically significantly.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmacology and is intended for extension of nomenclature of herbal medications for treatment of diabetes mellitus (DM). Studied are properties of Vaccinium axillare Nakai shoots, Far East plant, which had not been studied before. Glucose-tolerant test, made on male rats of Wistar line with weight 200-220 g, showed reliable hypoglycemic and glucosuric action of Vaccinium axillare Nakai shoots. Hypoglycemic effect of Vaccinium axillare Nakai is also confirmed in experiment on alloxan diabetes model. It has been established that newly studied plant activates glucose utilisation by brain, aggravated by angiopathy, at the background of alloxan diabetes.

EFFECT: obtained results indicate that Vaccinium axillare Nakai shoots have hypoglycemic and glucosuric effect and that new object has advantage in comparison with Vaccinium myrtillus due to more expressed hypoglycemic action and ability to activate glucose utilisation by brain in case of DM.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of medication, which possesses hepatoprotective, detoxicating and regenerating action. Medication contains in its composition essential phospholipids, vitamin B1, vitamin B2, vitamin B6, vitamin E, extract of milk thistle, extract of artichoke and auxiliary substances. Claimed medication extends arsenal of hepatoprotective medications, which possess wide pharmacologic spectrum of action.

EFFECT: medication corresponds to polyvalency of disease pathogenesis, affects patient's organism as a whole as corrective system.

2 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of medication, which possesses anti-inflammatory and regenerating action. Medication contains the following ingredients: conifer needle extract, purified oleoresin of cedar or pine, or spruce, or fir, or larch or their mixture in equal proportions, vegetable oil.

EFFECT: medication has increased effectiveness and efficiency and also extends arsenal of medications, which have anti-inflammatory and regenerating action.

7 cl, 9 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely, to method of obtaining preparation, which has immunomodulating, anti-inflammatory and wound-healing action, which lies in crushing preparation components dog rose fruit and/or ambrosia, drying to 10% humidity, freezing ambrozia and/or dog rose fruit separately to temperature 40-60°C with further impact on each component in jet mill by air jet under pressure 0.6-0.8 MPa until particles with size not more than 500 nm are obtained.

EFFECT: method ensures high productivity and good preservation of material properties.

2 tbl, 9 ex, 2 cl

FIELD: medicine.

SUBSTANCE: invention relates to cosmetology and represents cosmetic preparation, which contains derivative of vitamin E as a solubilising agent, represented by given below formula or its salt: where R1, R2 and R3 independently represent hydrogen atom or methyl group; R4 represents hydrogen atom, alkanoyl group which has from 1 to 6 carbon atoms, alkyl group, which has from 1 to 6 carbon atoms, group SO3H, group P(O)(OH)2, group CH2COOH or group COCH2 CH(SO3H)COOH; EO represents ethylene oxide group; BO represents butylene oxide group; k and n independently represent any of the numbers from 0 to 30 (however, k and n simultaneously do not take 0 value; and m represents any of the numbers from 0 to 30 and components, which are usually applied in cosmetic preparations.

EFFECT: invention ensures absence of stickiness during drying after application on skin, as well as improvement of solubilising and emulsifying ability.

7 cl, 13 ex, 5 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention relates to field of cosmetics. Composition, including, at least, one active component, selected from, at least, one antiperspirant active component and, at least, one deodorant active component, first gel-forming agent, selected from, at least, one fatty alcohol and, at least, one hydrocarbon of formula CnH2n+2, in which n has value from approximately 20 to approximately 100, and hydrocarbon, at least for 90% has linear structure; at least, one soya oil, which has iodine number from 0 to approximately 20; and, at least, one silicon-organic compound.

EFFECT: invention ensures antiperspirant and esthetic effect, without leaving visible deposit.

9 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of cosmetics. Composition, including, at least, one active component, selected from, at least, one antiperspirant active component and, at least, one deodorant active component, first gel-forming agent, selected from, at least, one fatty alcohol and, at least, one hydrocarbon of formula CnH2n+2, in which n has value from approximately 20 to approximately 100, and hydrocarbon, at least for 90% has linear structure; at least, one soya oil, which has iodine number from 0 to approximately 20; and, at least, one silicon-organic compound.

EFFECT: invention ensures antiperspirant and esthetic effect, without leaving visible deposit.

9 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of cosmetics. Composition, including, at least, one active component, selected from, at least, one antiperspirant active component and, at least, one deodorant active component, first gel-forming agent, selected from, at least, one fatty alcohol and, at least, one hydrocarbon of formula CnH2n+2, in which n has value from approximately 20 to approximately 100, and hydrocarbon, at least for 90% has linear structure; at least, one soya oil, which has iodine number from 0 to approximately 20; and, at least, one silicon-organic compound.

EFFECT: invention ensures antiperspirant and esthetic effect, without leaving visible deposit.

9 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of cosmetics. Composition, including, at least, one active component, selected from, at least, one antiperspirant active component and, at least, one deodorant active component, first gel-forming agent, selected from, at least, one fatty alcohol and, at least, one hydrocarbon of formula CnH2n+2, in which n has value from approximately 20 to approximately 100, and hydrocarbon, at least for 90% has linear structure; at least, one soya oil, which has iodine number from 0 to approximately 20; and, at least, one silicon-organic compound.

EFFECT: invention ensures antiperspirant and esthetic effect, without leaving visible deposit.

9 cl, 8 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to dentistry, and deals with medications for restoration of periodontal tissues and methods of their obtaining. Biotransplant for treatment of periodontal diseases represents suspension which contains cultures of autological or allogenic fibroblasts, or fibroblast-like cells in 0.9% solution of sodium chloride in concentration 2.0-10.0x106 in 1 ml of biotransplant, integrated on pharmaceutically acceptable biocompatible biodegradable carrier, selected from the group: acellular matrix, hyaluronic acid preparation, acellular matrix and hyaluronic acid preparation, with specified volume ratio of cell culture suspension ands carrier, which makes it possible to obtain consistence convenient for injecting and, together with expressed clinical effect ensures low traumaticity and simplicity of injecting. Preferable, as carrier, used is crushed to size 100-200 mcm acellular matrix "Saimetra". Also claimed is method of treating periodontal diseases, which lies in the following: on mucous membrane of gum in region of defect one week before biotransplant introduction preliminarily made are cuts provoking an acute inflammatory process resulting in increase of tissue volume, which makes it possible to carry out lossless introduction of large volume of biotransplant. After that, into defect area by means of injection two times with interval 1-4 weeks introduced is claimed biotransplant, using 3.6-60×106 cells per treatment course, which ensures optimal time interval for cell engraftment and restoration of periodontal tissues.

EFFECT: increase of treatment efficiency.

7 cl, 3 ex, 2 dwg

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

Up!